Edited by Philip Scheltens
This series of articles, published in Alzheimer's Research & Therapy, has not been sponsored. All articles have undergone the journal’s standard peer review process overseen by the Series Editor, with final decisions made by the Editors in Chief. The Series Editor and Editors in Chief declare no competing interests.
The symptomatic drugs currently on the market for Alzheimer’s disease (AD) have no effect on disease progression, and this creates a large unmet medical need. The type of drug that has developed most rapidly i...
Alzheimer’s disease (AD) is the most common cause of dementia and a major contributor to disability and dependency among older people. AD pathogenesis is associated with the accumulation of amyloid-beta protei...
Perhaps more definitively than any other class of novel Alzheimer’s disease (AD) therapy, pre-clinical studies in mouse models of amyloid β (Aβ) deposition have established the disease-modifying potential of a...
In the past decade, Alzheimer’s disease drug discovery has been directed at ‘disease modifying drugs’ that are able to counteract the progression of Alzheimer’s disease by intervening in specific parts of its ...